Research programme: stem cell therapeutics - BD/Fate Therapeutics
Latest Information Update: 16 Jul 2016
At a glance
- Originator Fate Therapeutics
- Developer Becton, Dickinson and Company; Fate Therapeutics
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in USA
- 15 Oct 2010 Early research in Undefined indication in USA (unspecified route)